{"id":"mm-398","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4114182","moleculeType":"Small molecule","molecularWeight":"518.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MM-398 (nal-IRI) encapsulates irinotecan in lipid nanoparticles that preferentially accumulate in tumors through passive targeting. This allows higher drug concentrations at the tumor site while reducing exposure to normal tissues, thereby improving the therapeutic index of irinotecan. The active metabolite SN-38 inhibits topoisomerase I, leading to DNA damage and cancer cell death.","oneSentence":"MM-398 is a liposomal formulation of irinotecan that delivers the topoisomerase I inhibitor directly to tumor cells while reducing systemic toxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:46.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin)"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":176},{"nctId":"NCT07479732","phase":"PHASE1, PHASE2","title":"Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-05","conditions":"Osteosarcoma, Osteosarcoma Metastatic","enrollment":56},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT07474103","phase":"NA","title":"SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-11-30","conditions":"Rectal Cancer, Adenocarcinoma","enrollment":49},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT07444918","phase":"PHASE2","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-01","conditions":"Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)","enrollment":33},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT03483038","phase":"PHASE2","title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-12-13","conditions":"Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT04150640","phase":"PHASE2","title":"Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-07-13","conditions":"Esophageal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":52},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT03785873","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-05-22","conditions":"Biliary Tract Cancer","enrollment":34},{"nctId":"NCT06219941","phase":"PHASE2","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer","enrollment":224},{"nctId":"NCT07397819","phase":"PHASE1, PHASE2","title":"Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy","status":"RECRUITING","sponsor":"Dong sheng Zhang","startDate":"2025-11-28","conditions":"Malignant Ascites","enrollment":48},{"nctId":"NCT04901702","phase":"PHASE1, PHASE2","title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-06-09","conditions":"Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma","enrollment":90},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT07030283","phase":"PHASE1","title":"Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-31","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":10},{"nctId":"NCT04005339","phase":"PHASE2","title":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2019-07-29","conditions":"Advanced Biliary Tract Cancer","enrollment":48},{"nctId":"NCT06821997","phase":"PHASE2","title":"NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-02-01","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT07281157","phase":"PHASE2","title":"Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11-01","conditions":"Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT04752696","phase":"PHASE2","title":"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2021-05-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":"Pancreatic Cancer","enrollment":328},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT04656041","phase":"PHASE2","title":"Folfox+Irinotecan+Chemort In Esophageal Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-29","conditions":"Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer","enrollment":40},{"nctId":"NCT07076212","phase":"PHASE2","title":"Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-07","conditions":"Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":52},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT05927857","phase":"PHASE1, PHASE2","title":"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2024-04-01","conditions":"Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy","enrollment":45},{"nctId":"NCT06258642","phase":"NA","title":"Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-17","conditions":"Small Cell Lung Cancer Recurrent","enrollment":39},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT05385861","phase":"PHASE1, PHASE2","title":"Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET","status":"ENROLLING_BY_INVITATION","sponsor":"National Health Research Institutes, Taiwan","startDate":"2025-08-14","conditions":"GEP-NET","enrollment":52},{"nctId":"NCT07123441","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sanjun Cai","startDate":"2025-09-01","conditions":"Colorectal Cancer","enrollment":300},{"nctId":"NCT07104604","phase":"PHASE1","title":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2025-08-01","conditions":"Rectal Cancer","enrollment":59},{"nctId":"NCT07085273","phase":"PHASE2","title":"Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-08-15","conditions":"Gastric Cancer","enrollment":33},{"nctId":"NCT07060014","phase":"PHASE1","title":"NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-07-18","conditions":"Advanced Small Intestine Cancer, Appendiceal Cancers","enrollment":22},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT03693677","phase":"PHASE2","title":"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-11-16","conditions":"Metastatic Pancreatic Cancer","enrollment":288},{"nctId":"NCT05277766","phase":"PHASE1","title":"Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2022-11-21","conditions":"Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer","enrollment":45},{"nctId":"NCT03764553","phase":"PHASE2","title":"Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-05-01","conditions":"Esophageal Cancer","enrollment":320},{"nctId":"NCT07026123","phase":"","title":"A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Advanced Pancreatic Cancer","enrollment":40},{"nctId":"NCT06135896","phase":"PHASE2","title":"Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-01-16","conditions":"Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma","enrollment":98},{"nctId":"NCT05854498","phase":"PHASE2","title":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-10-13","conditions":"Metastatic Colorectal Cancer","enrollment":25},{"nctId":"NCT07004712","phase":"PHASE2","title":"Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-06-01","conditions":"Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT06827717","phase":"PHASE2","title":"Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-15","conditions":"Ewing Sarcoma","enrollment":29},{"nctId":"NCT06438822","phase":"PHASE2","title":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-08-30","conditions":"Cholangiocarcinoma","enrollment":51},{"nctId":"NCT05383352","phase":"PHASE1","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-05-30","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":177},{"nctId":"NCT03328884","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-05-02","conditions":"Breast Cancer Metastatic","enrollment":55},{"nctId":"NCT03861702","phase":"PHASE2","title":"Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:","status":"COMPLETED","sponsor":"Nelson Yee","startDate":"2020-09-02","conditions":"Locally Advanced Pancreatic Carcinoma(LAPC)","enrollment":28},{"nctId":"NCT03468335","phase":"PHASE3","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-03-31","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":151},{"nctId":"NCT06894797","phase":"NA","title":"Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-01","conditions":"Locally Advanced Rectal Cancer","enrollment":68},{"nctId":"NCT06210971","phase":"PHASE2","title":"Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-02-01","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT04825288","phase":"PHASE1, PHASE2","title":"XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2021-05-27","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT03088813","phase":"PHASE3","title":"Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-04-25","conditions":"Small Cell Lung Cancer","enrollment":491},{"nctId":"NCT02631733","phase":"PHASE1","title":"Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-05-31","conditions":"Malignant Solid Neoplasm","enrollment":18},{"nctId":"NCT05472259","phase":"PHASE2","title":"A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)","status":"RECRUITING","sponsor":"Belgian Group of Digestive Oncology","startDate":"2022-05-25","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":134},{"nctId":"NCT03736720","phase":"PHASE2","title":"Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-17","conditions":"Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma","enrollment":11},{"nctId":"NCT06643793","phase":"PHASE2","title":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-11-04","conditions":"Colorectal Neoplasms Malignant","enrollment":30},{"nctId":"NCT06782685","phase":"PHASE1, PHASE2","title":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","status":"RECRUITING","sponsor":"Dai, Guanghai","startDate":"2024-06-23","conditions":"Advanced Pancreatic Cancer (Part 1)","enrollment":138},{"nctId":"NCT06657690","phase":"PHASE2","title":"Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":56},{"nctId":"NCT06766019","phase":"PHASE2","title":"Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-16","conditions":"Pancreatic Cancer","enrollment":47},{"nctId":"NCT03719924","phase":"PHASE2","title":"Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2019-03-07","conditions":"Squamous Cell Carcinoma","enrollment":106},{"nctId":"NCT03368963","phase":"PHASE1, PHASE2","title":"TAS102 in Combination With NAL-IRI in Advanced GI Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2018-01-30","conditions":"Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma","enrollment":64},{"nctId":"NCT06414577","phase":"PHASE2","title":"Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-22","conditions":"Nasopharyngeal Cancer","enrollment":38},{"nctId":"NCT03837977","phase":"PHASE2","title":"Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2018-11-13","conditions":"Oncology, Neuroendocrine Carcinoma","enrollment":58},{"nctId":"NCT06749691","phase":"PHASE2","title":"Liposomal Irinotecan and Apatinib in ES-SCLC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-12-28","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":30},{"nctId":"NCT06739928","phase":"PHASE2","title":"Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2025-01-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":120},{"nctId":"NCT05859750","phase":"PHASE2","title":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-05-25","conditions":"Pancreatic Cancer","enrollment":78},{"nctId":"NCT05049863","phase":"PHASE1","title":"Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2023-02-27","conditions":"Small-cell Lung Cancer, Small Cell Lung Carcinoma","enrollment":17},{"nctId":"NCT06405139","phase":"PHASE2","title":"Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Colorectal Cancer","enrollment":36},{"nctId":"NCT06710821","phase":"PHASE1","title":"Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Yizhuo Zhang","startDate":"2024-12-01","conditions":"Solid Tumor Cancer","enrollment":40},{"nctId":"NCT06700603","phase":"PHASE2","title":"Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-11-20","conditions":"Pancreatic Cancer","enrollment":48},{"nctId":"NCT06699459","phase":"PHASE2","title":"Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-11-14","conditions":"Biliary Tract Carcinoma","enrollment":76},{"nctId":"NCT06697366","phase":"PHASE2","title":"Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-20","conditions":"Gastric Cancer","enrollment":27},{"nctId":"NCT06688240","phase":"","title":"A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)","status":"NOT_YET_RECRUITING","sponsor":"Servier (Tianjin) Pharmaceutical Co. LTD.","startDate":"2024-11","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT06184698","phase":"PHASE2","title":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":173},{"nctId":"NCT06225999","phase":"PHASE2","title":"Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2024-04-25","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":41},{"nctId":"NCT02826486","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2016-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":80},{"nctId":"NCT06571461","phase":"PHASE3","title":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-09","conditions":"Pancreatic Cancer","enrollment":408},{"nctId":"NCT06341296","phase":"PHASE2","title":"Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-06-30","conditions":"Metastatic Colorectal Cancer","enrollment":86},{"nctId":"NCT06341309","phase":"PHASE1, PHASE2","title":"Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-08-09","conditions":"Metastatic Colorectal Cancer","enrollment":20},{"nctId":"NCT06475326","phase":"PHASE2","title":"Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-05","conditions":"Pancreatic Cancer","enrollment":87},{"nctId":"NCT06531278","phase":"PHASE2","title":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety","status":"RECRUITING","sponsor":"Jiang Long","startDate":"2024-07-16","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":40},{"nctId":"NCT04728035","phase":"PHASE1","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance","status":"COMPLETED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-05-31","conditions":"Advanced Breast Cancer","enrollment":119},{"nctId":"NCT02697058","phase":"PHASE2","title":"Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-03-30","conditions":"Metastatic Pancreatic Cancer","enrollment":84},{"nctId":"NCT03336216","phase":"PHASE2","title":"A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-18","conditions":"Advanced Pancreatic Cancer","enrollment":205},{"nctId":"NCT06513455","phase":"PHASE1, PHASE2","title":"Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-09-01","conditions":"Pancreatic Cancer","enrollment":132},{"nctId":"NCT06512428","phase":"PHASE2","title":"A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-03-15","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":138},{"nctId":"NCT06501664","phase":"PHASE3","title":"Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-08-01","conditions":"Esophageal Cancer","enrollment":360},{"nctId":"NCT05009953","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","status":"TERMINATED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-09-01","conditions":"Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma","enrollment":17},{"nctId":"NCT04727853","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)","status":"COMPLETED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-03-01","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":66},{"nctId":"NCT06478043","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-09-01","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":54},{"nctId":"NCT06467565","phase":"PHASE2","title":"NALIRIFOX as Induction Therapy in LAPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT06443307","phase":"","title":"Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-07-15","conditions":"Colorectal Cancer, Solid Tumor","enrollment":933},{"nctId":"NCT06434090","phase":"PHASE1, PHASE2","title":"Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-06-05","conditions":"Colorectal Cancer","enrollment":74},{"nctId":"NCT03337087","phase":"PHASE1, PHASE2","title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2018-11-02","conditions":"Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma","enrollment":18},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT04371224","phase":"PHASE2","title":"NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-06-23","conditions":"Pancreatic Cancer","enrollment":200},{"nctId":"NCT06370754","phase":"PHASE1, PHASE2","title":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-04-30","conditions":"Pancreatic Cancer","enrollment":117},{"nctId":"NCT06361316","phase":"NA","title":"Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Kuirong Jiang","startDate":"2024-04-08","conditions":"Pancreatic Cancer, Adjuvant Therapy","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GROUP A","GROUPE B","Onivyde","PEP02"],"phase":"phase_3","status":"active","brandName":"MM-398","genericName":"MM-398","companyName":"Ipsen","companyId":"ipsen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MM-398 is a liposomal formulation of irinotecan that delivers the topoisomerase I inhibitor directly to tumor cells while reducing systemic toxicity. Used for Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin), Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}